These results may have implications beyond NEPC, as TP53 plays a crucial role in restraining PRAD cancer cells from acquiring a mesenchymal, stem-like phenotype that is associated with ARSI resistance and poor clinical outcome (4, 50, 51). This evidence concerns the gene TP53 and cancer.